PGEN

Precigen Inc. (PGEN) | Rumor.io

Precigen

PGEN

Attention (50-day avg)0%

Attention rank (50-day avg)#1,029

Bullish sentiment (50-day avg)83%

Price to earnings ratio-5.7

Market capitalization2.8B

Earnings per share-1.07

Dividend yield (TTM)—

Revenue (annual)9.7M

Net income (annual)-250.6M

Social

What share of all stock conversation is about PGEN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% 0	0% 0	0% 0

Sep 25

B. Riley Securities initiates coverage on Precigen with a Buy rating and sets a price target of $12.
Precigen's Q2 2026 revenue reached $55.0M, more than double the prior quarter, and the company turned profitable for the quarter.
Analysts highlight Precigen's transition into a commercial-stage biotech following the FDA approval of Papzimeos, a first FDA-approved adult RRP therapy.

Generated by AI

Sentiment

Of the messages about PGEN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100% 0	86.05% +28.15	78.33% -7.11	83.22% -2.78
Bearish	0% 0	13.95% -28.15	21.67% +7.11	16.78% +2.78

Bullish· Aug 5

$PGEN's PRGN-2009 data is expected to drive the stock price to new heights, with the platform's ability to take an approval and commercialize it rapidly.
A HC Wainwright analyst has raised the price target to $18, considering PRGN-2009 as an upside to their valuation, and believing the company's AdenoVerse platform is well-suited for an FDA Platform Technology Designation.
The stock is expected to experience a significant squeeze due to its high short interest, 55% insider ownership, and blowout quarter, making any dip a huge buying opportunity.

Bearish· Aug 27

$PGEN's short interest may be trapped, making it difficult for bears to exit their positions.
The company's recent activity, including a Cantor fireside chat, may be timed to coincide with a bear raid, artificially lowering the stock price.
The large short interest in $PGEN, with over 29M shares short, may be a self-sustaining problem for bears, making it difficult for them to cover their positions.

Generated by AI

Topics

Of the messages about PGEN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	53.13%	28.57%	23.95%
Technical Analysis	—	1.56%	33.74%	16.32%
Earnings	—	0%	2.71%	3.46%
Analysts	—	45.31%	34.98%	23.44%
Controversies	—	0%	0%	0.31%
Macro	—	0%	0%	32.51%

Analysts· Aug 15

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Precigen $PGEN with a Buy and raises the price target from $6 to $8.5.
JP Morgan has adjusted their stance on Precigen ($PGEN), setting the rating to Neutral.
The FDA approval of Precigen's (PGEN) Papzimeos is very positive news for the company, with a reasonable target price post-approval estimated at $7 per share.

Announcements· Sep 8

Precigen secured up to $125 million in financing from Pharmakon Advisors, with $100 million funded upfront, to commercialize PAPZIMEOS.
The non-dilutive financing strengthens Precigen's balance sheet and provides the necessary runway to launch PAPZIMEOS, the first and only FDA-approved therapy for adult recurrent respiratory papillomatosis (RRP).
The financing deal gives Precigen investors a strengthened balance sheet and a commercialized product, but also ties the company to a loan with associated risks and rewards.

Technical Analysis· Aug 21

$PGEN is predicted to break through the $4 level, potentially leading to a significant price move.
The stock's RSI is currently at ~85, indicating it is in overbought territory, which may lead to a correction.
A potential resistance wall is forming around $4, which could be a key level to watch for a breakout.

Generated by AI

Community

Of the messages about PGEN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	85.71%	61.43%	54.56%	65.74%
Newcomers	14.29%	38.57%	45.44%	34.26%

Regulars· Sep 21

The FDA has granted Precigen's AdenoVerse platform technology designation, which can reduce regulatory uncertainty and help align trial designs earlier, cutting years off development cycles.
This designation is a significant boost to Precigen's pipeline, particularly for PRGN-2009, currently in Phase 2 trials for HPV-associated oropharyngeal squamous cell carcinoma and recurrent/metastatic cervical cancer.
The platform designation serves as a force multiplier for Precigen, shifting market perception from a company with single, isolated drug shots on goal to a validated plug-and-play platform company capable of systematically outputting regulatory-cleared therapeutics faster and cheaper.

Newcomers· Aug 5

The price target for PGEN has been raised to $18 from $14 by HC Wainwright, citing the potential for the FDA to designate AdenoVerse as a Platform Technology.
Newcomers are expecting a squeeze in PGEN, citing a high short interest percentage, low float, and a blowout quarter that beat both top and bottom line estimates.
PGEN has gapped up 5.1% premarket, but the thin volume may lead to a quick reversal, with some users watching the stock at the 7.35 level.

Generated by AI

Precigen, Inc. (NASDAQ:PGEN) announced on September 21 that the FDA granted Platform Technology Designation to AdenoVerse, the technology behind the approved medicine PAPZIMEOS. The designation creates opportunities to reuse manufacturing and preclinical knowledge in future drug applications, potentially reducing work that would otherwise need to be repeated. For Precigen, Inc. (NASDAQ:PGEN), the investment question is […]

1d agoYahoo Finance

Precigen (PGEN) Gains FDA Platform Backing, Is The Stock Still Cheap?

Precigen (PGEN) is back in focus after the United States Food and Drug Administration granted platform technology designation to its AdenoVerse immunotherapeutic platform, which underpins the recently approved PAPZIMEOS therapy. The recent FDA platform technology designation and the earlier approval of PAPZIMEOS have coincided with a sharp shift in market sentiment toward Precigen, with the share price delivering an 81.07% year-to-date return and a very large 3-year total shareholder return...

3d agoYahoo Finance

MRNA, PGEN Stocks Hit Multi-Year Highs – What’s Driving The Momentum Today?

Fresh analyst commentary put the spotlight on Moderna’s expanding mRNA cancer pipeline and Precigen’s transition into a commercial-stage biotech following the FDA approval of Papzimeos.

4d agoYahoo Finance

Precigen (PGEN) Secures FDA Platform Status For AdenoVerse And Future Therapies

Precigen (NasdaqGS:PGEN) said the FDA has granted platform technology designation to its AdenoVerse immunotherapeutic platform. The designation applies to the AdenoVerse platform rather than a single drug, covering multiple potential future product candidates across indications. FDA platform technology status can allow certain data and review learnings from one product to support later candidates built on the same backbone. The new FDA platform technology designation for AdenoVerse sits...

4d agoYahoo Finance

Precigen stock hits 52-week high at 8.05 USD

4d agoInvesting.com

B.Riley initiates Precigen stock coverage with buy on drug launch

5d agoInvesting.com

Also Discussed

Investors talking about PGEN also mention

#	Name	Attention
1	Alaunos Therapeutics Inc.TCRT	0%new
2	uniQure N.V.QURE	0.02%+0.01
3	Arcus Biosciences, Inc.RCUS	0%new
4	Kulicke & Soffa Industries, Inc.KLIC	0%0
5	Cullinan Therapeutics Inc.CGEM	0%new
6	Nurix Therapeutics, Inc.NRIX	0%new
7	Relay Therapeutics Inc.RLAY	0%new
8	Kymera Therapeutics Inc.KYMR	0%0
9	Tango Therapeutics Inc.TNGX	0%new
10	Pioneer Power Solutions Inc.PPSI	0%new

Precigen Inc.

Healthcare
Biotechnology

Precigen Inc. is a biopharmaceutical company focused on developing precision medicines for difficult-to-treat diseases. The company applies gene and cell therapy platforms to create targeted programs in immuno-oncology, autoimmune disorders, and infectious diseases. Its work centers on advancing innovative therapeutic candidates and related research tools that support discovery, preclinical development, and clinical development. Precigen also operates through business segments that include biopharmaceutical activities and specialized research-model services, giving it a broad presence across therapeutic development and life-science applications. Headquartered in Germantown, Maryland, Precigen serves as a clinical-stage innovator in the biotechnology sector, with an emphasis on translating proprietary technology platforms into potential treatments for patients with unmet medical needs.

Website

Location

20374 Seneca Meadows Parkway

Germantown, MD, 20876

United States

Social

What share of all stock conversation is about PGEN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% 0	0% 0	0% 0

Sep 25

B. Riley Securities initiates coverage on Precigen with a Buy rating and sets a price target of $12.
Precigen's Q2 2026 revenue reached $55.0M, more than double the prior quarter, and the company turned profitable for the quarter.
Analysts highlight Precigen's transition into a commercial-stage biotech following the FDA approval of Papzimeos, a first FDA-approved adult RRP therapy.

Generated by AI

Sentiment

Of the messages about PGEN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100% 0	86.05% +28.15	78.33% -7.11	83.22% -2.78
Bearish	0% 0	13.95% -28.15	21.67% +7.11	16.78% +2.78

Bullish· Aug 5

$PGEN's PRGN-2009 data is expected to drive the stock price to new heights, with the platform's ability to take an approval and commercialize it rapidly.
A HC Wainwright analyst has raised the price target to $18, considering PRGN-2009 as an upside to their valuation, and believing the company's AdenoVerse platform is well-suited for an FDA Platform Technology Designation.
The stock is expected to experience a significant squeeze due to its high short interest, 55% insider ownership, and blowout quarter, making any dip a huge buying opportunity.

Bearish· Aug 27

$PGEN's short interest may be trapped, making it difficult for bears to exit their positions.
The company's recent activity, including a Cantor fireside chat, may be timed to coincide with a bear raid, artificially lowering the stock price.
The large short interest in $PGEN, with over 29M shares short, may be a self-sustaining problem for bears, making it difficult for them to cover their positions.

Generated by AI

Topics

Of the messages about PGEN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	53.13%	28.57%	23.95%
Technical Analysis	—	1.56%	33.74%	16.32%
Earnings	—	0%	2.71%	3.46%
Analysts	—	45.31%	34.98%	23.44%
Controversies	—	0%	0%	0.31%
Macro	—	0%	0%	32.51%

Analysts· Aug 15

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Precigen $PGEN with a Buy and raises the price target from $6 to $8.5.
JP Morgan has adjusted their stance on Precigen ($PGEN), setting the rating to Neutral.
The FDA approval of Precigen's (PGEN) Papzimeos is very positive news for the company, with a reasonable target price post-approval estimated at $7 per share.

Announcements· Sep 8

Precigen secured up to $125 million in financing from Pharmakon Advisors, with $100 million funded upfront, to commercialize PAPZIMEOS.
The non-dilutive financing strengthens Precigen's balance sheet and provides the necessary runway to launch PAPZIMEOS, the first and only FDA-approved therapy for adult recurrent respiratory papillomatosis (RRP).
The financing deal gives Precigen investors a strengthened balance sheet and a commercialized product, but also ties the company to a loan with associated risks and rewards.

Technical Analysis· Aug 21

$PGEN is predicted to break through the $4 level, potentially leading to a significant price move.
The stock's RSI is currently at ~85, indicating it is in overbought territory, which may lead to a correction.
A potential resistance wall is forming around $4, which could be a key level to watch for a breakout.

Generated by AI

Community

Of the messages about PGEN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	85.71%	61.43%	54.56%	65.74%
Newcomers	14.29%	38.57%	45.44%	34.26%

Regulars· Sep 21

The FDA has granted Precigen's AdenoVerse platform technology designation, which can reduce regulatory uncertainty and help align trial designs earlier, cutting years off development cycles.
This designation is a significant boost to Precigen's pipeline, particularly for PRGN-2009, currently in Phase 2 trials for HPV-associated oropharyngeal squamous cell carcinoma and recurrent/metastatic cervical cancer.
The platform designation serves as a force multiplier for Precigen, shifting market perception from a company with single, isolated drug shots on goal to a validated plug-and-play platform company capable of systematically outputting regulatory-cleared therapeutics faster and cheaper.

Newcomers· Aug 5

The price target for PGEN has been raised to $18 from $14 by HC Wainwright, citing the potential for the FDA to designate AdenoVerse as a Platform Technology.
Newcomers are expecting a squeeze in PGEN, citing a high short interest percentage, low float, and a blowout quarter that beat both top and bottom line estimates.
PGEN has gapped up 5.1% premarket, but the thin volume may lead to a quick reversal, with some users watching the stock at the 7.35 level.

Generated by AI

Precigen

Social

Sep 25

Bullish· Aug 5

Bearish· Aug 27

Analysts· Aug 15

Announcements· Sep 8

Technical Analysis· Aug 21

Regulars· Sep 21

Newcomers· Aug 5

Precigen (PGEN) Gets FDA Recognition. Can it Cut the Cost of Developing New Drugs?

Precigen (PGEN) Gains FDA Platform Backing, Is The Stock Still Cheap?

MRNA, PGEN Stocks Hit Multi-Year Highs – What’s Driving The Momentum Today?

Precigen (PGEN) Secures FDA Platform Status For AdenoVerse And Future Therapies

Precigen stock hits 52-week high at 8.05 USD

B.Riley initiates Precigen stock coverage with buy on drug launch

Also Discussed

Precigen Inc.

Company Information

Location

Social

Sep 25

Bullish· Aug 5

Bearish· Aug 27

Analysts· Aug 15

Announcements· Sep 8

Technical Analysis· Aug 21

Regulars· Sep 21

Newcomers· Aug 5

Precigen (PGEN) Gets FDA Recognition. Can it Cut the Cost of Developing New Drugs?

Precigen (PGEN) Gains FDA Platform Backing, Is The Stock Still Cheap?

MRNA, PGEN Stocks Hit Multi-Year Highs – What’s Driving The Momentum Today?

Precigen (PGEN) Secures FDA Platform Status For AdenoVerse And Future Therapies

Precigen stock hits 52-week high at 8.05 USD

B.Riley initiates Precigen stock coverage with buy on drug launch

Also Discussed